Dexamphetamine treatment in stroke

QJM: An International Journal of Medicine

Volumn 96, Issue 9, 2003, Pages 673-685

  Long, D ^a   Young, John ^a  

^a ST LUKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE DERIVATIVE; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; DEXAMPHETAMINE; DOPAMINE; GANGLIOSIDE GM1; HALOPERIDOL; LEVODOPA; METHYLPHENIDATE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN; PLACEBO; PSYCHOSTIMULANT AGENT;

ABDOMINAL DISCOMFORT; ACUTE DISEASE; ANXIETY DISORDER; BEHAVIOR DISORDER; BRAIN INJURY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CLINICAL TRIAL; CONFUSION; CONVALESCENCE; DELUSION; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL ANIMAL; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MENTAL DISEASE; MOOD; MOTOR PERFORMANCE; NAUSEA; NEUROPHYSIOLOGY; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SENSORY STIMULATION; TREATMENT OUTCOME; URINE RETENTION; VISUAL DISORDER;

EID: 0042830914     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hcg113     Document Type: Review

References (92)

1. Bett WR. Benzedrine sulphate in clinical medicine: a survey of the literature. Postgrad Med J 1946; 22:205-18.
2. Anonymous. Amphetamines. Lancet 1969; 1(7598):765-6.
3. Clark ANG, Mankikar GD. d-Amphetamine in elderly patients refractory to rehabilitation procedures. J Am Geri Soc 1979; 27:174-7.
4. Hackett TP. Use of stimulant drugs in medicine. Address delivered at the American Psychiatric Association, 1978.
5. Hornstein A, Lennihan L, Seliger G, Lichtman S, Schroeder K. Amphetamine in recovery from brain injury. Brain Injury 1996; 10:145-8.
6. Lovell R. Lord Moran's prescriptions for Churchill [letter]. Br Med J 1995; 310:1537-8.
7. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetics drugs and adrenergic receptor antagonists. In: Wonsiewicz MJ, McCurdy P, eds. Goodman and Gilman's 'The Pharmacological Basis of Therapeutics.' McGraw-Hill, 1996:199-248.
8. Angrist B, Corwin J, Bartlik B, et al. Early pharmackinetic and clinical effects of oral d-amphetamine in normal subjects. Biol Psychiatry 1987; 22:1357-68.
9. Greenwald MK, Schuster CR, Johanson C-E, Jewell J. Automated measurement of motor activity in human subjects: effects of repeated testing and d-amphetamine. Pharmacol Biochem Behav 1998; 59:59-65.
10. Kumari V, Corr PJ, Mulligan OF, Cotter PA, Checkley SA, Gray JA. Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man. Psychopharmacology 1997; 129:271-6.
11. Soetens E, Casaer S, D'Hooge R, Hueting JE. Effect of amphetamine on long-term retention of verbal material. Psychopharmacology 1995; 119:155-62.
12. Brown RM, Carlson A, Ljunggren B, Siesjo BK, Snider SR. Effect of ischaemia on monoamine metabolism in the brain. Acta Physiol Scand 1974; 90:789-91.
13. Cohen HP, Waltz AG, Jacobson RL. Catecholamine content of cerebral tissue after occlusion or manipulation of middle cerebral artery in cats. J. Neurosurg 1975; 43:32-6.
14. Boyeson MG, Feeney DM. Intraventricular norepinephrine facilitates motor recovery following sensorimotor cortex injury. Pharm Biochem Behav 1990; 35:497-501.
15. Feeney DM, Gonzalez A, Law WA, Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 1982; 217:855-7.
16. Hovda DA, Feeney DM. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat. Brain Res 1984; 298:358-61.
17. Hurwitz BE, Dietrich WD, McCabe PM, Alonso O, Watson BD, Ginsberg MD, Schneiderman N. Amphetamine promotes recovery from sensory-motor integration deficit after thrombotic infarction of the primary somatosensory rat cortex. Stroke 1991; 22:648-54.
18. Feeney DM, Hovda DA. Reinstatement of binocular depth perception by amphetamine and visual experience after visual cortex ablation. Brain Res 1985; 342:352-6.
19. Nudo RJ, Plautz EJ, Frost SB. Role of adaptive plasticity in recovery of function after damage to motor cortex. Muscle Nerve 2001; 24:1000-19.
20. Nudo RJ, Wise BM, SiFuentes F, Milliken GW. Neural substrates for the effects of rehabilitative training on motor recovery after ischaemic infarct. Science 1996; 272:1791-4.
21. Kandel ER. Cellular mechanisms of learning and the biological basis of individuality. In: Kandel ER, Schwartz JH, Jessell TM, eds. Principles of Neural Science. McGraw Hill, 2000:1247-79.
22. Gold PE, Delanoy RL, Merrin J. Modulation of long-term potentiation by peripherally administered amphetamine and epinephrine. Brain Res 1984; 305:103-7.
23. Stroemer RP, Kent TA, Hulsebosch CE. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with d-Amphetamine therapy after neocortical infarction in rats. Stroke 1998; 29:2381-95.
24. Robinson TE, Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurones produced by previous experience with amphetamine. J Neurosci 1997; 17:8491-7.
25. Feeney DM, Baron J-C. Diaschiasis. Stroke 1986; 17:817-30.
26. Queen SA, Chen MJ, Feeney DM. d-Amphetamine attenuates decreased cerebral glucose utilization after unilateral sensorimotor cortex contusion in rats. Brain Res 1997; 777:42-50.
27. Saper CB. Brain stem modulation of sensation, movement and consciousness. In: Kandel ER, Schwartz JH, Jessell TM, eds. Principles of Neural Science. McGraw Hill, 2000:889-96.
28. Goldstein LB, Davis JN. Clonidine impairs recovery of beam-walking after a sensorimotor cortex lesion in the rat. Brain Res 1990; 508:305-9.
29. Sutton RL, Feeney DM. Noradrenergic agonists and antagonists affect recovery and maintenance of beam-walking ability after sensorimotor cortex ablation in the rat. Restor Neurol Neurosci 1992; 4:1-11.
30. Schmanke TD, Avery RA, Barth TM. The effects of amphetamine on recovery of function after cortical damage in the rat depend on the behavioural requirements of the task. J Neurotrauma 1996; 13:293-307.
31. Boyeson MG, Feeney DM. Adverse effects of catecholaminergic drugs following unilateral cerebellar ablations. Restor Neurol Neurosci 1991; 3:227-33.
32. Mintz M, Tomer R. Exposure to amphetamine after substantia nigra lesions interferes with the process of behavioural recovery. Pharmacol Biochem Behav 1986; 25:1307-11.
33. Virley D, Hadingham SJ, Campbell CA, Hunter J, Parsons AA. Deleterious effects of D-amphetamine on functional recovery following transient intraluminal suture MCAO in the rat [abstract]. Stroke 2001; 32:353.
34. Wang Y, Hayashi T, Chang C, Chiang Y, Tsao L, Su T, Borlongan C, Lin S. Methamphetamine potentiates ischemia/reperfusion insults after transient middle cerebral artery ligation. Stroke 2001; 32:775-82.
35. Crisostomo EA, Duncan PW, Propst M, Dawson DV, Davis JN. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann Neurol 1988; 23:94-7.
36. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee MD. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Stroke 1995; 26:2254-9.
37. Sonde L, Nordstrom M, Nilsson C-G, Lokk J, Viitanen M. A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke. Cerebrovasc Dis 2001; 12:253-7.
38. Martinsson L, Wahlgren NG. Safety of dexamphetamine in acute ischemic stroke: a randomised, double-blind, controlled dose-escalation trial. Stroke 2003; 34:475-81.
39. Mazagri R, Shuaib A, McPherson M, Deighton M. Amphetamine failed to improve motor function in acute stroke [abstract]. Can J Neurol Sci 1995; 22:S25.
40. Reding MJ, Borucki S. Effect of Dextroamphetamine on motor recovery after stroke abstract]. Neurology 1995; 45(Suppl. 4):A222.
41. Vachalathiti R, Asavavallobh C, Nilanont Y, Poungvarin N. Comparison of physical therapy and physical therapy with amphetamine in sensorimotor recovery of acute stroke patients: randomised controlled trial. J Neuro Sci 2001; 187(Suppl. 1):S253.
42. Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient: a method of evaluation of physical performance. Scand J Rehabil Med 1975; 7:13-31.
43. Cote R, Battista RN, Wolfson C, Bouccher J, Adam J, Hachinski V. The Canadian Neurological Scale: validation and reliability assessment. Neurology 1989; 39:638-43
44. Lindmark B, Hamrin E. Evaluation of functional capacity after stroke as a basis for active intervention: validation of a modified chart for motor capacity assessment. Scand J Rehab Med 1988; 20:111-15.
45. Scandinavian stroke study group. Multicentre trial of hemodilution in ischaemic stroke: background and study protocol. Stroke 1985; 16:855-90.
46. Walker-Batson D, Unwin H, Curtis S, et al. Use of amphetamine in the treatment of aphasia. Restor Neurol Neurosci 1992; 4:47-50.
47. Porch B. The Porch Index of Communicative Abilities. Palo Alto, Calif. Consulting Psychologists Press; 1982.
48. Walker-Batson D, Curtis S, Natarajan R, et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke 2001; 32:2093-8
49. Ziegler W, Muller U. Amphetamine in apraxia of speech [abstract]. International Congress on Stroke Rehabilitation (conference proceedings) 1993:71.
50. Muller U, Ziegler W, von Cramon DY. Amphetamine in apraxia of speech [abstract]. Neuropsychopharmacology 1994; 10 (Suppl. 3):226S.
51. Ziegler W, Hartmann E. The Munich Intelligibility Profile (MVP): reliability and validity. Nervenarzt 1993; 64:653-8.
52. Scheidtmann K, Fries W, Muller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet 2001; 358:787-90.
53. Bragoni M, Altieri M, Di Piero V, Padovani A, Mostardini C, Lenzi GL. Bromocriptine and speech therapy in non-fluent chronic aphasia after stroke. Neurol Sci 2000; 21:19-22.
54. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000; 75:711-21.
55. Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998; 79:1047-50.
56. Gladstone DJ, Black SE. Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Can J Neurol Sci 2000; 27:97-105.
57. Goldstein LB. Common drugs may influence motor recovery after stroke. Neurology 1995; 43:865-71.
58. Eames P. Head injury: behavioural modification. In: Goodwill CJ, Chamberlain MA, Evans C, eds. Rehabilitation of the physically disabled adult. Cheltenham, Stanley Thornes, 1997:414-31.
59. Hallett M, Wassermann EM, Cohen LG, Chielowska J, Gerloff C. Cortical mechanisms of recovery of function after stroke. NeuroRehabilitation 1998; 10:131-42.
60. Cramer SC, Nelles G, Benson RR, Kaplan JD, Parker RA, Kwong KK, Kennedy DN, Finklestein SP, Rosen BR. A functional MRI study of subjects recovered from hemiparetic stroke. Stroke 1997; 28:2518-27.
61. Silvestrini M, Cupini LM, Placidi F, Diomedi M, Bernardi G. Bilateral hemispheric activation in the early recovery of motor function after stroke. Stroke 1998; 29:1305-10.
62. Hamdy S, Aziz Q, Rothwell JC, Power M, Singh KD, Nicholson DA, Tallis RC, Thompson DG. Recovery of swallowing after dysphagic stroke relates to functional reorganization in the intact motor cortex. Gastroenterology 1998; 115:1104-12.
63. Classen J, Liepert J, Wise SP, Hallett M, Cohen LG. Rapid plasticity of human cortical movement representation induced by practice. J Neurophysiol 1998; 79:1117-23.
64. Butefisch CM, Davis BC, Sawaki L, Waldvogel D, Classen J, Kopylev L, Cohen LG. Modulation of use-dependent plasticity by d-amphetamine. Ann Neurol 2002; 51:59-68.
65. Butefisch CM, Davis BC, Wise SP, Sawaki L, Kopylev L, Classen J, L, Cohen LG. Mechanisms of use-dependent plasticity in the human motorcortex. Proc Natl Acad Sci USA 2000; 97:3661-5.
66. Uftring SJ, Wachtel SR, Chu D, McCandless C, Levin DN, de Wit H. An fMRI study of the effect of amphetamine on brain activity. Neuropsychopharm 2001; 25:925-35.
67. Mattay VS, Berman KF, Ostrem JL, Esposito G, Van Horn JD, Bigelow LB, Weinberger DR. Dextroamphetamine enhances 'neural network-specific' physiological signals: a positron-emission tomography rCBF study. J Neurosci 1996; 16:4816-22.
68. Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, Berman KF, Goldberg TE, Weinberger DR. Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 2000; 12:268-75.
69. Wheatley D. Amphetamines in General Practice: their use in depression and anxiety. Semin Psychiatry 1969; 1:163-73.
70. Overall JE, Hollister LE, Shelton J, Johnson M, Kimbell I. Tranylcypromine compared with dexamphetamine in hospitalised depressed patients. Dis Nerv Syst 1966; 27:653-9.
71. Spier SA. Toxicity and abuse of prescribed stimulants. Int J Psychiatr Med 1995; 25:69-79.
72. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psych 2000; 61:436-40.
73. Wroblewski B. Epileptic potential of stimulants, dopaminergics, and antidepressants. J Head Trauma Rehabil 1992; 7:109-11.
74. Livingston S, Pauli LL. Dextroamphetamine for epilepsy. JAMA 1975; 233:278-9.
75. Bakheit AMO. Intracerebral haemorrhage in previously healthy young adults. Postgrad Med J 1999; 75:499-500.
76. D'Souza T, Shraberg D. Intracranial hemorrhage associated with amphetamine use. Neurology 1981; 31:922-3.
77. Petitti DB, Sidney S. Quesenberry C, Bernstein A. Stroke and cocaine or amphetamine abuse. Epidemiology 1998; 9:596-600.
78. Yen DJ, Wang SJ, Ju TH, Chen CC, Liao KK, Fuh JL, Hu HH. Stroke associated with methamphetamine inhalation. Eur Neurol 1994; 34:16-22.
79. Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989; 50:241-9.
80. Woods SW, Tesar GE, Murray GB, Cassem NH. Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry 1986; 47:12-15.
81. Masand P, Pickett P, Murray GB. Psychostimulants for secondary depression in medical illness. Psychosomatics 1991; 32:203-8.
82. Unwin H, Walker-Batson D. No side-effects after low-dose amphetamine administration in stroke rehabilitation. Stroke 2000; 31:1788-9.
83. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. Sleep 1994; 17:352-71.
84. Starkstein SE, Fedoroff JP, Price TR, Leiguarda R, Robinson RG. Apathy following cerebrovascular lesions. Stroke 1997; 28:2437-41.
85. Robinson RG. Treatment issues in post-stroke depression. Depression Anxiety 1998; 8(S1):85-90.
86. Reding MJ, Orto LA, Winter SW et al. Antidepressant therapy after stroke: a double-blind trial. Arch Neurol 1986; 43:763-5.
87. Gonzalez-Torrecillas JL, Mendlewicz J, Lobo A. Effects of early treatment of post-stroke depression on neuropsychological rehabilitation. Int Psychogeriatr 1995; 7:547-60.
88. Chemerinski E, Robinson RG, Kosier JT. Improved recovery in activities of daily living associated with remission of post-stroke depression. Stroke 2001; 32:113-17.
89. Block SD for the ACP-ASIM End-of-Life Care Consensus Panel. Assessing and managing depression in the terminally ill patient. Ann Intern Med 2000; 132:209-18.
90. Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001; 50:718-29.
91. Goldstein LB (co-ordinator), Dromerick AW, Good DC, Lennihan L, Rabadi M. National Institute of Neurologic Diseases and Stroke, Maryland USA (Sponsors). The Amphetamine Enhanced Stroke Recovery (AESR) trial. [http://www.strokecenter.org/trials/TrialDetail.asp?ref=427]
92. Cohen LG (co-ordinator). National Institute of Neurologic Diseases and Stroke, Maryland USA (Sponsors). Motor recovery in recent stroke patients treated with amphetamine and physical therapy. [http://www.strokecenter.org/trials/TrialDetail.asp?ref=143]